Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 3
1951 2
1952 4
1953 3
1954 2
1955 2
1956 1
1957 3
1958 2
1959 2
1960 3
1961 8
1962 9
1963 12
1964 19
1965 17
1966 26
1967 17
1968 18
1969 20
1970 26
1971 35
1972 34
1973 22
1974 28
1975 27
1976 24
1977 24
1978 59
1979 41
1980 40
1981 34
1982 57
1983 59
1984 65
1985 74
1986 62
1987 76
1988 69
1989 110
1990 85
1991 80
1992 83
1993 103
1994 114
1995 94
1996 95
1997 121
1998 102
1999 126
2000 122
2001 133
2002 138
2003 161
2004 141
2005 119
2006 135
2007 138
2008 157
2009 152
2010 173
2011 173
2012 218
2013 205
2014 227
2015 232
2016 198
2017 227
2018 228
2019 227
2020 278
2021 279
2022 146
Text availability
Article attribute
Article type
Publication date

Search Results

5,853 results
Results by year
Filters applied: . Clear all
Page 1
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. Drilon A, et al. Among authors: hayashi h. Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13. Nat Med. 2020. PMID: 31932802 Free PMC article.
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, Tanizaki J, Tanaka K, Takeda M, Ogura T, Ishida T, Ito A, Nakagawa K. Isomoto K, et al. Among authors: hayashi h. Clin Cancer Res. 2020 Apr 15;26(8):2037-2046. doi: 10.1158/1078-0432.CCR-19-2027. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937613
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.
Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. Jänne PA, et al. Among authors: hayashi h. Cancer Discov. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21. Cancer Discov. 2022. PMID: 34548309 Clinical Trial.
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, Tanizaki J, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K. Suzuki S, et al. Among authors: hayashi h. Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7. Clin Cancer Res. 2021. PMID: 34365406
Exosome-Derived microRNA-22 Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation in Vitro and in Vivo.
Kuse N, Kamio K, Azuma A, Matsuda K, Inomata M, Usuki J, Morinaga A, Tanaka T, Kashiwada T, Atsumi K, Hayashi H, Saito Y, Seike M, Gemma A. Kuse N, et al. Among authors: hayashi h. J Nippon Med Sch. 2020 Jul 13;87(3):118-128. doi: 10.1272/jnms.JNMS.2020_87-302. Epub 2019 Nov 28. J Nippon Med Sch. 2020. PMID: 31776321 Free article.
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.
Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Tanizaki J, et al. Among authors: hayashi h. Ann Oncol. 2022 Feb;33(2):216-226. doi: 10.1016/j.annonc.2021.11.009. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34843940 Free article. Clinical Trial.
Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance.
Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, Hayashi H, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Yashiro M, Masuda M, Ajani JA, Tan P, Baba H, Ishimoto T. Uchihara T, et al. Among authors: hayashi h. Cancer Res. 2020 Aug 15;80(16):3222-3235. doi: 10.1158/0008-5472.CAN-19-3803. Epub 2020 Jun 30. Cancer Res. 2020. PMID: 32605995
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K. Hayashi H, et al. JAMA Oncol. 2020 Dec 1;6(12):1931-1938. doi: 10.1001/jamaoncol.2020.4643. JAMA Oncol. 2020. PMID: 33057591 Free PMC article. Clinical Trial.
5,853 results